JP2018521007A - Ｌ−４−クロロキヌレニンの治療的使用 - Google Patents

Ｌ−４−クロロキヌレニンの治療的使用 Download PDF

Info

Publication number
JP2018521007A
JP2018521007A JP2017560663A JP2017560663A JP2018521007A JP 2018521007 A JP2018521007 A JP 2018521007A JP 2017560663 A JP2017560663 A JP 2017560663A JP 2017560663 A JP2017560663 A JP 2017560663A JP 2018521007 A JP2018521007 A JP 2018521007A
Authority
JP
Japan
Prior art keywords
chlorokynurenine
depression
treatment
administration
tinnitus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017560663A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018521007A5 (enExample
Inventor
スノードグラス、エイチ．ラルフ
ザ サード、アレン イー． ケイトー
ザ サード、アレン イー． ケイトー
エス． ヒックリン、ジャック
エス． ヒックリン、ジャック
Original Assignee
ヴィスタゲン セラピューティクス、インコーポレイテッド
ヴィスタゲン セラピューティクス、インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヴィスタゲン セラピューティクス、インコーポレイテッド, ヴィスタゲン セラピューティクス、インコーポレイテッド filed Critical ヴィスタゲン セラピューティクス、インコーポレイテッド
Publication of JP2018521007A publication Critical patent/JP2018521007A/ja
Publication of JP2018521007A5 publication Critical patent/JP2018521007A5/ja
Priority to JP2022004811A priority Critical patent/JP2022064908A/ja
Priority to JP2024000227A priority patent/JP2024050575A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017560663A 2015-05-22 2016-05-23 Ｌ−４−クロロキヌレニンの治療的使用 Pending JP2018521007A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022004811A JP2022064908A (ja) 2015-05-22 2022-01-17 Ｌ－４－クロロキヌレニンの治療的使用
JP2024000227A JP2024050575A (ja) 2015-05-22 2024-01-04 Ｌ－４－クロロキヌレニンの治療的使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562179924P 2015-05-22 2015-05-22
US62/179,924 2015-05-22
PCT/US2016/033733 WO2016191351A1 (en) 2015-05-22 2016-05-23 Therapeutic uses of l-4-chlorokynurenine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022004811A Division JP2022064908A (ja) 2015-05-22 2022-01-17 Ｌ－４－クロロキヌレニンの治療的使用

Publications (2)

Publication Number Publication Date
JP2018521007A true JP2018521007A (ja) 2018-08-02
JP2018521007A5 JP2018521007A5 (enExample) 2019-06-20

Family

ID=57393671

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017560663A Pending JP2018521007A (ja) 2015-05-22 2016-05-23 Ｌ−４−クロロキヌレニンの治療的使用
JP2022004811A Pending JP2022064908A (ja) 2015-05-22 2022-01-17 Ｌ－４－クロロキヌレニンの治療的使用
JP2024000227A Pending JP2024050575A (ja) 2015-05-22 2024-01-04 Ｌ－４－クロロキヌレニンの治療的使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022004811A Pending JP2022064908A (ja) 2015-05-22 2022-01-17 Ｌ－４－クロロキヌレニンの治療的使用
JP2024000227A Pending JP2024050575A (ja) 2015-05-22 2024-01-04 Ｌ－４－クロロキヌレニンの治療的使用

Country Status (19)

Country Link
US (3) US20180140568A1 (enExample)
EP (2) EP3297619B1 (enExample)
JP (3) JP2018521007A (enExample)
KR (2) KR20240068766A (enExample)
CN (1) CN107949379A (enExample)
AU (3) AU2016268153B2 (enExample)
BR (1) BR112017024908A2 (enExample)
CA (1) CA3024783A1 (enExample)
DK (1) DK3297619T3 (enExample)
EA (1) EA201792571A1 (enExample)
ES (1) ES2925274T3 (enExample)
IL (3) IL296380A (enExample)
MX (1) MX395492B (enExample)
PL (1) PL3297619T3 (enExample)
PT (1) PT3297619T (enExample)
SG (1) SG10202007661XA (enExample)
SI (1) SI3297619T1 (enExample)
WO (1) WO2016191351A1 (enExample)
ZA (1) ZA201707874B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3598971B1 (en) 2013-01-22 2024-03-20 Vistagen Therapeutics, Inc. Dosage forms and therapeutic uses of l-4-chlorokynurenine
EP3870292A4 (en) 2018-10-26 2022-11-09 The Research Foundation for The State University of New York COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA
US20220202756A1 (en) * 2019-04-09 2022-06-30 Vistagen Therapeutics, Inc. Genetic variants associated with response to treatment of neurological disorders
WO2021262914A1 (en) * 2020-06-24 2021-12-30 Biohaven Therapeutics Ltd. Compositions and methods for treating obsessive-compulsive disorder
WO2022221423A1 (en) * 2021-04-13 2022-10-20 Vistagen Therapeutics, Inc. Treatment of autoimmune anti-nmda-receptor encephalitis
CN115677519A (zh) * 2021-07-22 2023-02-03 立科时代(武汉)生物科技有限公司 L-4-溴-犬尿氨酸及其在制备治疗抑郁症药物中的应用
WO2024011105A1 (en) * 2022-07-05 2024-01-11 Mahana Therapeutics, Inc. Methods and systems for treating tinnitus using digital therapeutics

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004515477A (ja) * 2000-12-07 2004-05-27 ニューロモレキュラー インコーポレイテッド Ｎｍｄａレセプターアンタゴニストを用いて神経精神医学的障害を処置するための方法
JP2009510047A (ja) * 2005-09-28 2009-03-12 アウリス メディカル アクチエンゲゼルシャフト 蝸牛興奮毒性によって誘導される耳鳴りを処置する方法
JP2011503013A (ja) * 2007-11-06 2011-01-27 エモリー・ユニバーシテイ 安全なｎｍｄａ受容体拮抗薬を同定する方法
WO2014031975A1 (en) * 2012-08-23 2014-02-27 Weg Stuart L Anxiolytic composition, formulation and method of use
WO2014116739A1 (en) * 2013-01-22 2014-07-31 Vistagen Therapeutics, Inc. Dosage forms and therapeutic uses l-4-chlorokynurenine

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5484814A (en) 1991-02-28 1996-01-16 Merrell Dow Pharmaceuticals Inc. NMDA antagonists
AU2981099A (en) * 1998-03-09 1999-09-27 Trustees Of Tufts College Treatment of compulsive behaviours in man and animals
TW518218B (en) * 1999-05-27 2003-01-21 Merck Patent Gmbh Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders
CA2649209A1 (en) * 2006-04-12 2007-10-18 Probiodrug Ag Enzyme inhibitors
CA2606658A1 (en) * 2006-10-13 2008-04-13 Mike Tyers Compositions and methods for treating neurological disorders or damage
TW201026667A (en) * 2008-09-30 2010-07-16 Merz Pharma Gmbh & Co Kgaa Glycine b antagonists
WO2014152835A1 (en) 2013-03-14 2014-09-25 Vistagen Therapeutics, Inc. Synthesis of chiral kynurenine compounds and intermediates
CN105164100B (zh) 2013-03-14 2017-09-15 维斯塔津治疗公司 用于合成手性犬尿氨酸化合物的方法
RU2721948C2 (ru) * 2014-05-06 2020-05-25 Нортвестерн Юниверсити Комбинации соединений, модулирующих nmda-рецептор

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004515477A (ja) * 2000-12-07 2004-05-27 ニューロモレキュラー インコーポレイテッド Ｎｍｄａレセプターアンタゴニストを用いて神経精神医学的障害を処置するための方法
JP2009510047A (ja) * 2005-09-28 2009-03-12 アウリス メディカル アクチエンゲゼルシャフト 蝸牛興奮毒性によって誘導される耳鳴りを処置する方法
JP2011503013A (ja) * 2007-11-06 2011-01-27 エモリー・ユニバーシテイ 安全なｎｍｄａ受容体拮抗薬を同定する方法
WO2014031975A1 (en) * 2012-08-23 2014-02-27 Weg Stuart L Anxiolytic composition, formulation and method of use
WO2014116739A1 (en) * 2013-01-22 2014-07-31 Vistagen Therapeutics, Inc. Dosage forms and therapeutic uses l-4-chlorokynurenine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Facilitated brain uptake of 4-chlorokynurenine and conversion to 7-chlorokynurenic acid", NEUROREPORT, vol. 8, JPN6020010528, 1996, pages 15 - 18, ISSN: 0004437480 *
"糖尿病性ニューロパチーの病態と治療", 臨床神経, vol. 49, JPN6020010529, 2009, pages 149 - 157, ISSN: 0004437479 *

Also Published As

Publication number Publication date
US20240122887A1 (en) 2024-04-18
AU2016268153B2 (en) 2021-08-12
DK3297619T3 (da) 2022-08-15
EP4108239A1 (en) 2022-12-28
KR20240068766A (ko) 2024-05-17
JP2022064908A (ja) 2022-04-26
HK1257800A1 (en) 2019-11-01
SI3297619T1 (sl) 2023-02-28
PT3297619T (pt) 2022-08-05
EP3297619A1 (en) 2018-03-28
EA201792571A1 (ru) 2018-06-29
KR20180015158A (ko) 2018-02-12
CA3024783A1 (en) 2016-12-01
AU2023282234A1 (en) 2024-01-18
ZA201707874B (en) 2020-01-29
AU2021209279B2 (en) 2023-09-14
SG10202007661XA (en) 2020-09-29
WO2016191351A1 (en) 2016-12-01
JP2024050575A (ja) 2024-04-10
BR112017024908A2 (pt) 2018-07-31
EP3297619A4 (en) 2019-01-02
EP3297619B1 (en) 2022-07-06
IL296380A (en) 2022-11-01
MX395492B (es) 2025-03-25
AU2016268153A1 (en) 2017-12-14
AU2021209279A1 (en) 2021-08-19
IL255770A (en) 2018-01-31
US20190321317A1 (en) 2019-10-24
PL3297619T3 (pl) 2023-02-13
MX2017014456A (es) 2018-03-16
ES2925274T3 (es) 2022-10-14
US20180140568A1 (en) 2018-05-24
IL285882A (en) 2021-09-30
IL255770B (en) 2021-09-30
CN107949379A (zh) 2018-04-20

Similar Documents

Publication Publication Date Title
AU2021209279B2 (en) Therapeutic uses of L-4-chlorokynurenine
Detke et al. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial
WO2020105005A1 (en) Methods of treating rett syndrome using fenfluramine
AU2011313814B2 (en) Combination therapy for the treatment of depression and other non-infectious diseases
JP2024069257A (ja) Ｌ－４－クロロキヌレニンの剤形及び治療的使用
Karp et al. Rescue pharmacotherapy with duloxetine for selective serotonin reuptake inhibitor nonresponders in late-life depression: outcome and tolerability.
KR20250069706A (ko) 도파민성 cns 장애의 치료에서 ly3154207의 사용을 위한 용량 요법
US7786126B2 (en) Combination preparations comprising SLV308 and a dopamine agonist
Gomez-Bernal et al. Vitamin B12 deficiency manifested as mania: a case report
HK1257800B (en) Therapeutic uses of l-4-chlorokynurenine
WO2007144421A1 (en) Combination preparations comprising slv308 and a l-dopa
JP2008513430A (ja) 月経前症候群および月経前不快気分障害の処置のためのピンドロール
KR20230154968A (ko) 파킨슨병 진행을 늦추기 위한 메비달렌 및 다른 d1 양성 알로스테릭 조절제의 용도
TW202416952A (zh) 治療cns病症之方法
HK40059702A (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
Bon et al. Absence of cardiac side effects during treatment of schizophrenia with risperidone in a patient with Wolff-Parkinson-White syndrome
Malhotra et al. Case Report: Bupropion-Induced Claustrophobia
HK1116664A (en) Use of n-desmethylclozapine to treat human neuropsychiatric disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180406

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180406

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190513

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190513

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200311

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200317

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200615

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200811

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200917

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210202

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210506

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210702

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210917